Competition
Competition - Ginkgo Bioworks (DNA)
Competitive Bottom Line
Ginkgo's claimed moat — being the only public company doing horizontal cell programming across pharma, ag, industrial and biosecurity — is partly real but partly an artefact of the rest of the field being too small or too vertical to want what Ginkgo is selling. The platform is broader and better-instrumented than any vertical peer, but in FY2025 it was the only listed synbio-platform peer with revenue shrinking (-32% YoY) while four of five comparators grew 19% to 27%. The competitor that matters most is not another listed name — it is the customer's own in-house R&D, which Ginkgo's 10-K names as the primary alternative for cell engineering work. Among public peers, Twist Bioscience (tools that scale at 20%+ with improving unit economics) and Schrödinger (the only FCF-positive peer in this cohort in FY2025) are the relevant proof-points that a TechBio platform can reach breakeven — Ginkgo has not yet shown either.
Currency: USD. Market data as of 2026-05-08; FY2025 fundamentals from each company's most recent 10-K.
The Right Peer Set
The five comparators below come straight from Ginkgo's own FY2025 10-K "Competition" section (business.txt L364-398) and were retained after a cross-check against external coverage. Each peer maps to a named category in the disclosure: AbCellera (antibody discovery) and Codexis (enzymes) are the named "verticalized cell engineering platforms"; Recursion and Schrödinger are the largest listed examples of the "newer AI entrants in the emerging TechBio area"; Twist Bioscience is the closest synbio-tools comparable, both a supplier to Ginkgo (commercial collaboration revised in May 2025) and a partial workflow substitute. CROs and integrated-automation peers named in the same section (Charles River, Evotec, WuXi Biologics, Thermo Fisher, HighRes Biosolutions, Automata) are excluded as peer-multiple comparators because their scale ($1B-$40B revenue) or business model (regulated CDMO, diversified tools) makes their unit economics non-comparable to a $170M-revenue platform — they appear in the threat map instead.
Reading the chart. DNA sits at the far left (the only peer with negative growth) at 3.6x EV/revenue, only slightly above Codexis. The premium-multiple peers (RXRX, ABCL) trade on drug-pipeline optionality and large net-cash positions, not revenue. Twist is the only peer priced as a tools business: 9.2x revenue, 20% growth, improving FCF. If Ginkgo's autonomous-lab pivot succeeds, Twist is the template; if it does not, the comparable is CDXS at 3.8x.
The peer-set tell. Across five FY25 comparators, only DNA had declining revenue. Even Codexis — which lost half its revenue in FY2023 after Pfizer's mRNA program collapsed — grew 19% in FY2025 on its own restructured base. DNA's revenue decline is a 2022-COVID-biosecurity overhang plus genuine cell-engineering contraction; whichever it is, the peer group has now lapped its respective declines and DNA has not.
Where The Company Wins
Competitive scorecard - DNA vs five public peers (1=weak, 5=strong)
The heatmap shows the shape clearly: DNA's column has the most 4s and 5s in the top half (structural dimensions - breadth, automation, library, government, gross margin) and slips to 1s and 2s in the bottom half (revenue trajectory, FCF). Peers SDGR and TWST show the opposite pattern — weaker structural endowment, stronger execution. The investment question is whether DNA's structural advantages convert into execution metrics before the cash optionality compresses.
Where Competitors Are Better
The chart makes the picture vivid: DNA is the only peer in the bottom-left quadrant (negative growth and burning more than 1x revenue). SDGR is the upper-right outlier (positive growth, FCF-positive). TWST sits comfortably mid-right (growing 20% while burning only 20% of revenue). The market is paying the highest EV/revenue multiple for the lowest combined burn-and-grow scores (SDGR, TWST). Note ABCL's +160% headline is a base-effect: FY22 included $216M of Lilly bamlanivimab royalty income that evaporated in FY23 — strip that, and ABCL's underlying services revenue is far smaller and slower.
Threat Map
The two High-severity threats share a structural feature. Both customer-in-house R&D and Twist's encroachment imply that Ginkgo's monetization is bounded above by whatever customers can do cheaply themselves with off-the-shelf tools and DNA synthesis. The platform's economics work only if Datapoints and RACs offer something the buyer cannot rebuild — and the buyer is now better-equipped than at any point since Ginkgo's IPO to make that buy-vs-build decision favorably to itself.
Moat Watchpoints
Five quarterly-observable signals that will tell an investor whether the competitive position is durably improving or quietly weakening.
Two-line summary. If the next four quarters deliver even one external RAC anchor + a Datapoints repeat-rate disclosure + burn at the low end of guide, the moat case is supported and the platform has a path toward TWST-style multiples. If two of those three fail to materialize, the right comparator is Codexis at 3–4x revenue and the structural advantages stop earning a premium.